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Dear Editor,
We congratulate Buti et al. [1] for their beautiful meta-anal-
ysis on all available clinical data from randomized clinical 
trials evaluating the impact of immune checkpoint inhibitors 
(CKI) on the outcomes of patients with metastatic renal cell 
carcinoma (mRCC) in first-line setting. In their work, the 
authors showed that immunotherapy-based combinations 
were able to decrease the risk of death over the standard 
of care by 26% (HR 0.74; 95% confidence interval (CI) 
0.60–0.92; p = 0.006), to decrease the risk of progression 
by 21% (HR 0.79; 95% CI 0.72–0.86; p < 0.00001), and to 
increase the relative risk of response by 40% (HR 1.40; 95% 
CI 1.11–1.77; p = 0.006). The authors did not report data on 
adverse events that are a relevant topic when a new treatment 
option arises. In particular, several studies showed that suni-
tinib is associated with a significant risk of developing all- 
and high-grade hypothyroidism [2], while endocrine dys-
functions among patients receiving CKI regimens were well 
described [3]. On the basis of these findings, which show a 
possible risk of hypothyroidism for both sunitinib and CKI, 
it could seem reasonable to extend the analyses performed 
by Buti et al. for the evaluation of the risk of hypothyroidism 
in patients who received immunotherapy-based combina-
tions versus sunitinib.
The pooled analysis with a random-effects model revealed 
that the incidence of any grade hypothyroidism among sub-
jects with CKI combinations was quite similar compared 
to subjects with sunitinib (risk rate (RR) = 1.03, 95% CI 
0.72–1.46; p = 0.88; I2 = 88%; Fig. 1). The pooled analy-
sis with a fixed-effects model revealed that the incidence 
of grade ≥ 3 hypothyroidism was higher without a statisti-
cally significance in patients treated with sunitinib than CKI 
combinations (RR = 1.14, 95% CI 0.41–3.13; p = 0.81; I2 = 0; 
Fig. 2). In conclusion, nonetheless, our analysis presents 
limitations, such as different experimental arm combina-
tions; literature review rather than a meta-analysis based on 
individual patients’ data and, therefore, definitive conclu-
sions need to be considered carefully; our data confirmed no 
increasing incidence in the RR for any grade and grade ≥ 3 
hypothyroidism with CKI combinations for mRCC.  
This comment refers to the article available online at https ://doi.
org/10.1007/s1209 4-020-02292 -z.
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Fig. 1  Forest plots of risk rate (RR) for any grade hypothyroidism comparing experimental to sunitinib. The Chi-squared test showed high het-
erogeneity between the trials. The random-effects model was used
Fig. 2  Forest plots of risk rate (RR) for grade ≥ 3 hypothyroidism comparing experimental to sunitinib. The Chi-squared test showed low hetero-
geneity between the trials. The fixed effects model was used
